Urology · Tyler, TX
NPI
1811937378
Since 2006
Specialty
Urology
Code 208800000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
700 Olympic Plaza Cir, Ste 700
Tyler, TX, 75701
Phone (903) 262-3900
Groups this clinician bills Medicare through
Medicare paid, 2024
$106K
5,124 services
Medicare patients, 2024
303
Average age 76
Drug cost, 2024
$139K
1,338 prescriptions
Company payments, 2025
$47.45
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Thomas C Bright III was code Q9967 (low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml), 1,500 times for 15 patients. In total Thomas C Bright III billed 5,124 services in 51 codes, and Medicare paid $106K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-08-14.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,500 | 15 | $0.11 | $161 |
| 99214 Office E&M - Established | Office | 476 | 263 | $89.08 | $42K |
| 36415 Venipuncture Blood Collection | Office | 214 | 152 | $8.65 | $1,851 |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 132 | 15 | $139.84 | $18K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 113 | 15 | $47.25 | $5,340 |
| 51798 Ultrasound - Nonspecific | Office | 78 | 67 | $8.05 | $628 |
| 81002 Clinical Chemistry | Office | 67 | 42 | $3.41 | $228 |
| 99204 Office E&M - New | Office | 62 | 62 | $109.59 | $6,795 |
| 52000 Cystourethroscopy | Office | 55 | 44 | $166.38 | $9,151 |
| 74176 CT/CTA - Abdomen and Pelvis | Office | 25 | 19 | $71.21 | $1,780 |
| 96402 Chemotherapy Administration | Office | 22 | 15 | $21.72 | $478 |
| 74178 CT/CTA - Abdomen and Pelvis | Office | 22 | 22 | $180.54 | $3,972 |
| 99213 Office E&M - Established | Office | 18 | 18 | $50.29 | $905 |
By year: 2022 $118K for 2,576 services; 2023 $106K for 1,944 services; 2024 $106K for 5,124 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 214 | 152 | $8.65 | $1,851 |
| 81002 Clinical Chemistry | 67 | 42 | $3.41 | $228 |
Medicare prescription drug claims, 2024
In 2024, the drug Thomas C Bright III prescribed most often to Medicare patients was Tamsulosin Hcl, with 553 prescriptions and refills. In total Thomas C Bright III wrote 1,338 Medicare prescriptions that cost $139K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 553 | 1,104 | 149 | $7,787 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 203 | 302 | 68 | $12K |
| Myrbetriq Mirabegron | 101 | 156 | 30 | $68K |
| Oxybutynin Chloride Generic | 71 | 160 | 24 | $1,229 |
| Ciprofloxacin Hcl Generic | 61 | 61 | 51 | $242 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 57 | 68 | 34 | $423 |
| Solifenacin Succinate Generic | 56 | 109 | 17 | $1,846 |
| Gemtesa Vibegron | 34 | 66 | Under 11 | $30K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 25 | 60 | 11 | $447 |
| Finasteride Generic | 19 | 60 | Under 11 | $334 |
| Silodosin Generic | 17 | 31 | Under 11 | $1,724 |
| Mirabegron Er Mirabegron | 16 | 36 | Under 11 | $8,395 |
| Trimethoprim Generic | 14 | 30 | Under 11 | $647 |
| Nitrofurantoin Nitrofurantoin Macrocrystal | 12 | 26 | Under 11 | $1,283 |
Brand drugs: 221 claims; generic drugs: 1,117 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Thomas C Bright III $47.45 ($47.45 in general payments such as food, travel and fees) from 1 company. The largest payer was Boston Scientific Corporation with $47.45.
| Company | Payments | Amount |
|---|---|---|
| Boston Scientific Corporation BSX | 2 | $47.45 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.